Impact of dialysate calcium concentration on the progression of aortic stiffness in patients on haemodialysis Correspondence and offprint requests to: Mohsen Agharazii; E-mail: mohsen.agharazii@crhdq.ulaval.ca Abstract Background. Higher dialysate calcium (DCa) can result in an acute and transient increase in arterial stiffness. The aim of the present study is to evaluate the impact of DCa on the progression of arterial stiffness, calcium balance and bone metabolism in haemodialysis (HD) patients over a 6-month period. Method. We randomly assigned 30 patients on chronic HD to be dialysed with a DCa of 1.12 or 1.37 mmol/L for a period of 6 months. Aortic stiffness and brachial stiffness were respectively measured by carotid-femoral pulse wave velocities (cf-PWV) and carotid-radial pulse wave velocity (cr-PWV) at baseline and at 3 and 6 months. Central pulse pressure (PP) and augmentation index were determined by radial artery tonometry. Dialysis calcium balance and parathyroid hormone (PTH) were measured monthly. Procollagen type-1 amino-terminal propeptide (P1NP) and C-terminal telopeptide of type-I collagen (CTX) were measured as markers of bone formation and resorption, respectively. Data was analysed by linear mixed model. Results. Twenty-seven patients (66 6 13 years old) with a mean duration of HD of 5.8 6 3.6 months completed the study. At baseline, the groups were similar with respect to age, serum levels of calcium, phosphate and PTH, blood pressure (BP), cf-PWV and cr-PWV. The cf-PWV at baseline and 3 and 6 months were, respectively, 13.4 6 4.2, 14.7 6 3.31 and 13.6 6 2.5 m/s in the DCa 1.12 group and 14.6 6 5.9, 15.8 6 7.8 and 17.0 6 7.0 m/s in the DCa 1.37 group. After correction for mean BP, cf-PWV increased with DCa 1.37 as compared to DCa 1.12 (Time-DCa interaction P ¼ 0.002). However, there were no significant effects of DCa on progression of cr-PWV, central PP or augmentation index. During the intervention period, the mean PTH was slightly higher in the DCa 1.12 group as compared to the DCa 1.37 group (325 6 185 versus 211 6 128 ng/L, P ¼ 0.054), and dialysis calcium balance was À8.1 6 4.4 versus À0.2 6 4.7 mmol/session, respectively, in groups with DCa 1.12 and DCa 1.37 (P ¼ 0.0001). Treatment with DCa 1.12 mmol/L resulted in increasing levels of CTX as compared to DCa 1.37 (P ¼ 0.02), whereas the P1NP levels did not change significantly in either group.
Introduction
The high prevalence of cardiovascular disease among haemodialysis (HD) patients cannot be explained solely by traditional cardiovascular risk factors. More recently, aortic stiffness, as measured by carotid-femoral pulse wave velocity (PWV), has been shown to be an independent predictor for cardiovascular morbidity and mortality in a HD population [1, 2] . Physiologically, increased stiffness of the large elastic arteries leads to increased central pulse pressure (PP), cardiac workload and left ventricular hypertrophy [3] [4] [5] [6] [7] . The relationship between calcium-containing phosphate binders and vascular calcification has raised concerns about the long-term effects of chronic positive calcium balance [8, 9] . However, the concerns about calcium-containing phosphate binders have overshadowed the importance of dialysate calcium (DCa) concentration in the overall calcium balance. Although Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines recommend a DCa concentration of 1.25 mmol/L [10] , the optimal DCa also depends on other factors such as the use of specific phosphate binders, vitamin D or vitamin D analogues, frequency and length of HD sessions and cardiovascular stability [11] [12] [13] . The Dialysis Outcomes and Practice Patterns Study revealed that the average dialysate Ca concentration was 1.45 mmol/L, with~60% of patients exceeding the 1.25 mmol/L that was recommended by K/DOQI. In addition, the data show an excess risk of all-cause mortality by 13% for each increase in DCa of 0.5 mmol/L [14] .
Previously, investigators have studied the role of DCa on arterial stiffness in short-term studies. These studies suggest that higher DCa concentrations are associated with a transient and reversible increase in arterial stiffness [15] [16] [17] [18] [19] . This transient modulation of arterial stiffness is most likely mediated through an increase in serum-ionized calcium (iCa) levels, which in turn increases vascular smooth muscle tone. However, the impact of DCa on the rate of progression of arterial stiffness over a longer period of time remains unknown.
In light of the current knowledge, the aim of the present study was to compare the effects of two DCa concentrations on the progression of aortic and brachial stiffness over a 6-month period. We also determined the amount of dialysis-related calcium balance and studied the effects of these two DCa on markers of bone formation and resorption over a 6-month period.
Materials and methods
This was a single-centre prospective, randomized unblinded study comparing a DCa concentration of 1.12 mmol/L (DCa-1.12) versus DCa concentration of 1.37 mmol/L (DCa-1.37) for a period of 6 months. The study was conducted at Centre Hospitalier Universitaire de Québec-L' Hôtel-Dieu de Québec Hospital, between September 2006 and September 2009. Eligibility criteria for the study included age >18 years, HD vintage between 3 and 18 months, stable dry weight, single-pool KT/V >1.4, stable doses of antihypertensive medications, phosphate binders and dialysis prescription over the month preceding inclusion into the study, the ability to obtain reliable haemodynamic measurements and informed consent. Patients were excluded if they had any clinical conditions that would hamper haemodynamic measurements [atrial fibrillation, absence of femoral pulse, amputation or systolic blood pressure (SBP) of <90 mmHg], SBP >180 mmHg , haemoglobin <90 g/L, acute clinical conditions (infection, heart failure, active bleeding), history of parathyroidectomy, parathyroid hormone (PTH) >800 ng/L or calciphylaxis. Patients were also excluded if their expected survival was <6 months. These inclusion and exclusion criteria were used to insure the reliability of haemodynamic measurements, to avoid significant changes in therapeutic strategies during the study period and to reduce the possibility of dropouts during the study period.
Randomization was stratified for decade of age and presence or absence of diabetes. Following randomization, the patients were treated by the assigned DCa for a period of 6 months. Arterial stiffness and markers of bone metabolism were measured at baseline and 3 and 6 months. Dialysis calcium balance was performed monthly, and the calcium-based phosphate binders and non-calcium-based phosphate binders were adjusted every 2 weeks to keep the serum calcium levels within normal limits (2.15-2.55 mmol/L) and phosphate levels <1.8 mmol/L. Haemodialysis was performed three times weekly with dialysis duration of 3-4 h, a blood flow of 350-400 mL/min. A bicarbonate-based buffer dialysis solution was used with sodium concentrations of 138-142 mmol/L, potassium concentrations of 1-4 mmol/L and a dialysate flow rate of 500 to 750 mL/min. The study was approved by the institution review board and was conducted in accordance to the declaration of Helsinki. All patients provided written informed consent.
Haemodynamic measurements
Haemodynamic measurements were performed just prior to the mid-week dialysis session between 7 and 9 AM, at baseline and after 3 and 6 months of treatment with the assigned DCa. These measurements were performed in a quiet room outside the HD unit and after 15 min of rest in a supine position prior to haemodynamic measurements. Brachial artery BP was recorded using an automatic sphygmomanometer BPM-100 (BP-Tru, Coquitlam, Canada). BP was recorded six times, with a 2-min interval between each measurement, and the average of the last five measurements was used to determine the brachial SBP and diastolic blood pressure [20] . We determined carotid-femoral pulse wave velocity (cf-PWV) and carotid-radial pulse wave velocity (cr-PWV) using foot-to-foot method (CompliorÒ SP; Artech Medical, Pantin, France) as described previously [19, 21] . Briefly, the sensors were positioned over carotid, radial and femoral arteries and the transit times were determined. Three consecutive recordings were performed to determine the transit time, followed by measurement of direct distance between the two probes to calculate PWV by dividing the travel distance by transit time. In order to assess the impact of arterial stiffness on central pulse wave profile, radial pulse wave profile was recorded by aplanation tonometry after recalibration with systolic and diastolic brachial BP (SphygmoCor systemÒ; AtCor Medical Pty. Ltd., Sydney, Australia). Three consecutive recordings were performed and central pulse wave profile was constructed using the generalized transfer function as previously described and validated [19, 22] . Central SBP, DBP, mean blood pressure, PP, time of return of the reflected wave (Tr), central augmented pressure (AP) and heart rate-adjusted central augmentation index (AIx) [AIx ¼ (AP/PP) 3 100] were determined ( Figure 1 ).
Markers of bone metabolism
Blood sample were taken at baseline and 3 and 6 months between 7 and 9 AM after an overnight fast for the measurement of procollagen type 1 amino-terminal propeptide (P1NP) as a marker of bone formation and C-terminal cross-linking telopeptide of type-I collagen (CTX) as a marker of bone resorption using electrochemiluminescence assays on an Elecsys analyser (Roche Diagnostics, Montreal, Canada).
Calcium balance studies
At baseline and monthly during the study period, each patient underwent a dialysis session for determination of dialysis calcium balance. Dialysis calcium balance was determined by using a continuous partial collection of pre-and post-filter dialysis fluid and determination of the amount of used dialysis fluid and total ultrafiltration (QuatiscanÒ; Hospal, Zaventen, Belgium). The calcium concentration was determined in both solutions and calcium balance was determined as previously described [23] .
Biochemical measurements
Blood samples were obtained immediately before the start of each HD session. Ionized Ca was measured with an ion-selective electrode on a Nova PhoxPlus analyser. PTH was measured with the PTH stat assay from 
Results
Thirty chronic HD patients met the initial inclusion criteria and provided informed consent to participate in the study. Three patients were excluded prior to the second evaluation at 3 months for the following reasons: one was transplanted (DCa-1.37), one was unwilling to continue (DCa-1.12) and one developed calciphylaxis within the first 2 weeks of using a DCa of 1.37 mmol/L. Between the third and fourth month, one patient died but his participation in the study was retained for the first 3 months. Therefore, 27 patients were available for the final analysis. The baseline characteristics for the assigned treatment groups are shown in Table 1 , which shows that the two groups were similar with regard to age, comorbidities, duration of dialysis, parameters of mineral metabolism and medication. The baseline central BP, AIx, cr-PWV and cf-PWV were also similar in both groups (Table 2) . During the intervention, all HD sessions were performed with the assigned DCa.
The impact of the DCa over time on the progression of aortic and brachial stiffness is shown in Figure 2 . In a linear mixed model (Table 3) after adjustment for the mean BP at each time point, there is a significant effect of DCa on the progression of aortic stiffness between two groups (P ¼ 0.002 for Time-DCa interaction), whereas there were no significant effects of DCa on the progression of brachial artery stiffness (P ¼ 0.758 for Time-DCa interaction). We observed no significant effect of DCa on changes in central PP, central AIx or Tr. The parameters of estimate for cf-PWV are shown in Table 4 .
The mean dialysis calcium balance per session were À8.1 AE 4.4 versus À0.2 AE 4.7 mmol/session, respectively, in groups DCa-1.12 and DCa-1.37 (P ¼ 0.0001) (Figure 3) . The mean iCa, phosphate, phosphate binders and vitamin D were not significantly different among the two groups (Table  5) . However, the mean PTH level during the study period was higher in DCa-1.12 as compared to DCa-1.37 (P ¼ 0.054).
The impact of DCa on the markers of bone metabolism is shown in Figure 4 and Table 6 . Treatment with DCa 1.12 mmol/L resulted in increasing levels of CTX, a marker of bone resorption (P ¼ 0.02 for Time-DCa interaction), whereas the P1NP levels (marker of bone formation) did not change significantly over the study period in either group (P ¼ 0.809 for Time-DCa interaction).
Discussion
In this study, we evaluated the impact of a DCa of 1.12 versus 1.37 mmol/L on the progression of arterial stiffness and regulation of bone metabolism over a 6-month period. Our results show for the first time that DCa of 1.37 mmol/L resulted in the progression of aortic stiffness, whereas aortic stiffness did not change significantly with the DCa of 1.12 mmol/L. In contrast, there were no significant changes in the brachial stiffness in either group. The lower DCa concentration resulted in a negative dialysis calcium balance that remained constant over time and resulted in increasing bone resorption during the study period.
Previously, short-term studies had shown that higher DCa can have a significant effect on arterial stiffness [15] [16] [17] [18] [19] . However, it was proposed that this acute, transient and reversible calcium-dependent increase in arterial stiffness was functional and was most likely the result of variation in vascular smooth muscle cell (VSMC) tone that is highly dependent on the extracellular calcium concentration. Since elastin, which provides the elasticity to the blood vessel, is aligned in series with the VSMC, an increase in VSMC tone transfers the energy from the elastin onto the VSMC and leads to an increase in the functional stiffness of the arteries. In the present study, the ionized calcium concentration was not different between groups and was well within normal limits during the study period. Therefore, it is reasonable to assume that the changes of aortic stiffness over time were not related to changes in the serum-ionized calcium levels and VSMC tone. In addition, since the progression of aortic stiffness in DCa 1.37 group was independent of changes in mean BP, it suggests that progression of aortic stiffness in DCa-1.37 were not of a functional nature. The differential impact of DCa on the progression of aortic and brachial stiffness underlines the heterogeneity of the arterial tree in both structure and function. Aorta is an elastic vessel that provides the principal capacitive element of the arterial tree, whereas the brachial artery is a medium-sized muscular vessel with primarily a conductive function. This distinction is essential when examining arterial stiffness both in terms of pathophysiology and in terms of clinical outcome. In this regard, Pannier et al. [24] showed that only aortic stiffness had a prognostic value in predicting cardiovascular outcome, whereas brachial stiffness and femorotibial stiffness did not provide this prognostic value. Although PP and AIx have previously been used to assess arterial stiffness, these two parameters may also be influenced by other factors such as stroke volume, heart rate, reflection sites and mean BP. Therefore, the absence of a relationship between Time-DCa interaction and PP or AIx simply underlines the inability of these parameters to act as reliable and pure indicators of arterial stiffness [25, 26] . In our view, the different results are explained by the complexity and heterogeneous nature of both structure and function of arterial tree.
The dialysis calcium removal was nearly neutral in DCa-1.37 and negative by 8 mmol/session in DCa-1.12. Therefore, it can be assumed that total calcium balance might have been positive in DCa-1.37 and negative in DCa-1.12 since the daily oral calcium and vitamin D treatment was similar between the two groups during the study period. A negative calcium balance in DCa-1.12 resulted in a slight increase in PTH levels (P ¼ 0.054) and CTX (bone resorption), without any significant changes in the bone formation (P1NP). This observation suggests that dialysis with DCa 1.12 mmol/L increases bone resorption over time to compensate for the negative dialysis calcium balance. From a perspective of bone metabolism, this observation warrants against a DCa of 1.12 mmol/L, especially in the context of relatively limited oral calcium and low doses of vitamin D as it was the case in our study.
It could be argued that a high number of exclusion criteria might reduce the applicability of these findings to the general dialysis population. These exclusion criteria were to avoid selection and survival bias and to create two homogeneous groups of subjects with little potential for other contaminants during the study period. More specifically, we wanted to reduce the probability of a major therapeutic change in antihypertensive regimen, erythropoietin dose, use of pharmacological doses of vitamin D or calcimimetics, which could have potentially contaminated the final interpretation of the findings. Furthermore, because of controversies around the PTH levels in dialysis and the DCa concentration, it was thought that clinical nephrologists would not have accepted that patients with PTH >800 ng/ L be treated with a DCa of 1.12 mmol/L. Patients with leg amputations and impalpable femoral pulse were excluded as amputations could alter pulse wave reflection sites and AIx, and the presence of femoral pulse is essential for measurement of cf-PWV. We voluntarily aimed to exclude patients with longer dialysis vintage in order to reduce the impact of a survival bias and potentially avoid patients with advanced chronic kidney disease-related vascular disease. Despite these exclusion criteria, our study subjects (40% with diabetes, 60% with coronary artery disease and mean age of 67 years) were quite similar to the average dialysis population. We acknowledge that there are some limitations to the present study. Firstly, the study is relatively small and a 6-month period can be considered to be relatively short compared to the life of a dialysis patient. Secondly, it would have been interesting to evaluate the effects of a DCa of 1.25 as it is commonly used, at least in North America [14] . However, some compromise was in order to assure patient recruitment and retainment. In the absence of previous data, we presumed that a difference of 0.25 mmol/L between two DCa concentrations would be clinically relevant to see a difference in the rate of progression of aortic stiffness in this population. Therefore, we concluded that DCa 1.12 versus 1.37 mmol/ L for a limited period of 6 months would not cause a major objection by the treating nephrologists and would not seriously hamper patient enrolment. In the end, the groups were comparable at baseline with respect to age, dialysis vintage, haemodynamic and mineral metabolism parameters. Finally, although the study was small and unblinded, the evaluation of arterial stiffness was performed first by determining the transit time in triplicates, followed by the measurement of the distance between probes once the transit time was determined. Therefore, it is unlikely that the results were influenced by the observer who performed the measurements.
In conclusion, we showed for the first time that DCa concentration plays an important role in the overall calcium balance of HD patients and contributes significantly to the rate of progression of aortic stiffness that is independent of mean BP and ionized serum calcium concentrations. Consequently, DCa concentration could be considered a risk factor for progressive aortic stiffness in HD patients. In the context of limited oral calcium, the long-term safety of DCa 1.12 mmol/L on bone metabolism remains to be established. More studies are required to evaluate the impact of DCa on arterial stiffness and bone metabolism over a longer period of time. 
